Latest Venlafaxine Stories
PITTSBURGH, Dec. 8 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc.
WILMINGTON, Del., Dec.
However, bupropion XL and mirtazapine can benefit people suffering from depression.
The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to investigate whether patients with depression benefit from taking drugs belonging to the selective serotonin and norepinephrine reuptake inhibitor (SNRI) drug class.
WALTHAM, Mass., Aug.
Researchers from the FDA released an analysis on Tuesday that showed people under age 25 who take antidepressants have a higher risk of suicide, but adults older than that do not.
Combining antidepressant drugs with electroconvulsive therapy (ECT) does a better job of reducing symptoms of severe depression and causes less memory loss than using ECT alone, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.
Only 41 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources Patient-Flow Models Need to Take Into Account Effexor XR's More Frequent Use in Early Lines of Therapy Compared With Cymbalta WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that one third of surveyed psychiatrists and two...
Use of Atypicals In Major Depression Treatment Is Growing, According to a New Report from Decision Resources Patient-Flow Forecasts Between Pristiq and Effexor XR Need to Take Into Account Reimbursement Hurdles WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of major...
Lexicon Pharmaceuticals, a biopharmaceutical company, has successfully completed a second Phase I clinical trial of LX1032, an orally-delivered small molecule drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome.